Clinical Development of Cell Therapies: Setting the Stage for Academic Success

被引：18

作者：

Abou-El-Enein, M. ^{[1
,2
]}

Volk, H-D ^{[1
,3
]}

Reinke, P. ^{[1
,2
]}

机构：

[1] Charite, Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany

[2] Charite, Dept Nephrol & Internal Intens Care, Berlin, Germany

[3] Charite, Inst Med Immunol, Berlin, Germany

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / 01期

关键词：

D O I：

10.1002/cpt.523

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cellular therapies have potential to treat a wide range of diseases with autologous immunotherapies showing unprecedented therapeutic promise in clinical trials. Such therapies are mainly developed by academic researchers applying small-scale production, targeting rare and unmet medical needs. Here, we highlight the clinical translation of immunotherapy product in an academic setting, which may serve as a success model for early academic development of cell-based therapeutics.

引用

页码：35 / 38

页数：4

共 8 条

[1]

[Anonymous], 2016, PDUFA REAUTH PERF GO

[2] Innovation in the pharmaceutical industry: New estimates of R&D costs [J].

DiMasi, Joseph A. ;

Grabowski, Henry G. ;

Hansen, Ronald W. .

JOURNAL OF HEALTH ECONOMICS, 2016, 47 :20-33

[3]

EFPIA MID3 Workgroup et al, 2016, CPT PHARMACOMETRICS, V5, P93

[4]

KMR Group, 2015, SUCC RAT DEV LARG VS

[5]

Pharmaprojects, 2016, BLOCKB TRENDS RIS ST

[6] Organizational effectiveness: a key to R&D productivity [J].

Tollman, Peter ;

Panier, Valery ;

Dosik, Diana ;

Biondi, Paul ;

Cuss, Francis .

NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (07) :441-442

[7]

U. S. Food and Drug Administration, 2016, OV DRUGS 2015 SUMM

[8]

US Food and Drug Administration, 1998, GUID IND PROV CLIN E

← 1 →